Akcea Therapeutics
140 articles with Akcea Therapeutics
-
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics
10/12/2020
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics, Inc. (NASDAQ: AKCA). The combination of Ionis and Akcea accelerates the next phase of Ionis' gr
-
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
-
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
8/31/2020
Ionis to acquire remaining 24% of common stock of Akcea it does not already own for $18.15 per share in cash
-
Shares of Akcea Therapeutics were up more than 58% in premarket trading after its majority owner Ionis Pharmaceuticals announced it will acquire all outstanding shares of the company, which amounts to about 24% of available stock for $18.50 per share.
-
Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020
8/29/2020
Results in late-breaking presentation show patients with hypertriglyceridemia experienced dose-dependent reductions in triglyceride levels, apoC-III, and significant reductions in atherogenic lipoproteins
-
Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020
8/29/2020
Results from Phase 2 study demonstrate patients receiving vupanorsen experienced significant, dose-dependent reductions in triglyceride levels, ANGPTL3 and additional lipid parameters compared to placebo
-
Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020
8/24/2020
Late-breaking presentation to focus on efficacy and safety data of vupanorsen in patients with hypertriglyceridemia, type 2 diabetes and non-alcoholic fatty liver disease
-
Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
8/18/2020
Data presentation will highlight efficacy, safety and tolerability of investigational medicine in patients with hypertriglyceridemia and cardiovascular disease
-
Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
8/13/2020
WAYLIVRA is the only treatment option for patients with familial chylomicronemia syndrome, or FCS, in Europe
-
Akcea Reports Financial Results and Highlights for Second Quarter 2020
8/4/2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2020.
-
BioSpace Movers & Shakers, July 24
7/24/2020
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. -
Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
7/22/2020
TEGSEDI is the first antisense oligonucleotide medicine available to hATTR patients with polyneuropathy in Austria for at-home subcutaneous injection TEGSEDI is now commercially available in 15 countries
-
Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
7/21/2020
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and report on pipeline and business progress.
-
Akcea Appoints New Senior Vice President, Global Medical Affairs
7/20/2020
Dr. Christophe Hotermans joins company, with a decade of clinical practice and 12 years of experience in global biotechnology sector.
-
BioSpace Movers & Shakers, July 10
7/10/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Akcea Announces Appointment of New Chief Medical Officer
7/9/2020
Dr. William Andrews brings two decades of global industry experience, including more than 13 years in rare diseases and seven product launches
-
Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
6/29/2020
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced that Tracy Palmer Berns has joined the company as chief compliance officer.
-
Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
6/17/2020
Akcea Therapeutics, Inc. announced that Damien McDevitt, chief executive officer, and Kyle Jenne, chief commercial officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference, which is being held virtually, on Tuesday, June 23, 2020 at 3:30 p.m. ET.
-
BioSpace Movers & Shakers, June 12
6/12/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
6/9/2020
Dr. Kia Motesharei joins from Merck KGaA, bringing more than 20 years of experience in the pharmaceutical and biotechnology industry [09-June-2020] BOSTON , June 9, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei , Ph.D., has joined the company as Senior Vice